Literature DB >> 22410542

Retention of an autologous endothelial layer on a bioprosthetic valve for the treatment of chronic deep venous insufficiency.

Casey M Jones1, Monica T Hinds, Dusan Pavcnik.   

Abstract

PURPOSE: Percutaneous transcatheter implantation of porcine small intestinal submucosa (SIS) bioprosthetic valves has been reported as a treatment for chronic deep venous insufficiency (CDVI). Endothelial progenitor outgrowth cells (EOCs), isolated from whole ovine blood, were evaluated as a source of in vitro autologous seeding for SIS endothelialization. Retention of the EOC monolayer was evaluated to test the feasibility of delivering an endothelialized SIS valve.
MATERIALS AND METHODS: Twenty bioprosthetic venous valves were constructed from SIS sutured onto collapsible square stent frames and were seeded with ovine EOCs in vitro. Retention of the endothelial monolayer through valve loading and delivery (three valves), in vitro flow (three valves), and ex vivo flow (four valves) was evaluated with immunofluorescent staining and histologic analysis compared with paired unmanipulated control valves. In the ex vivo shunt loop, venous blood was pulled from an implanted dialysis catheter, through the valve, and returned to the sheep.
RESULTS: Immunofluorescent staining of EOCs on the valves after in vitro seeding revealed a confluent monolayer (95.6% ± 2.3% confluent) on each side of the valve. When examined by immunofluorescent staining, the endothelial monolayer remained intact after loading and delivery (97.1% ± 1.7%) and when subjected to flow in the in vitro loop (96.0% ± 3.0%). Histologic analysis of the valves subjected to the ex vivo shunt loop revealed retention of the endothelial monolayer.
CONCLUSIONS: Endothelial monolayers seeded on SIS were retained under loading and delivery, in vitro flow, and ex vivo flow. EOCs are a promising cell source for autologous endothelialization of bioprosthetic valves for the treatment of CDVI.
Copyright © 2012 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22410542      PMCID: PMC3336010          DOI: 10.1016/j.jvir.2012.01.062

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  16 in total

1.  The biocompatibility of titanium cardiovascular devices seeded with autologous blood-derived endothelial progenitor cells: EPC-seeded antithrombotic Ti implants.

Authors:  Hardean E Achneck; Ryan M Jamiolkowski; Alexandra E Jantzen; Justin M Haseltine; Whitney O Lane; Jessica K Huang; Lauren J Galinat; Michael J Serpe; Fu-Hsiung Lin; Madison Li; Amar Parikh; Liqiao Ma; Tao Chen; Bantayehu Sileshi; Carmelo A Milano; Charles S Wallace; Thomas V Stabler; Jason D Allen; George A Truskey; Jeffrey H Lawson
Journal:  Biomaterials       Date:  2010-11-05       Impact factor: 12.479

2.  Tissue-engineered bioprosthetic venous valve: a long-term study in sheep.

Authors:  O E Teebken; C Puschmann; T Aper; A Haverich; H Mertsching
Journal:  Eur J Vasc Endovasc Surg       Date:  2003-04       Impact factor: 7.069

Review 3.  Vascular repair by endothelial progenitor cells.

Authors:  Anna Zampetaki; John Paul Kirton; Qingbo Xu
Journal:  Cardiovasc Res       Date:  2008-03-18       Impact factor: 10.787

Review 4.  Percutaneous management of chronic deep venous reflux: review of experimental work and early clinical experience with bioprosthetic valve.

Authors:  Dusan Pavcnik; Barry Uchida; John Kaufman; Monica Hinds; Frederick S Keller; Josef Rösch
Journal:  Vasc Med       Date:  2008-02       Impact factor: 3.239

5.  Percutaneous therapy for deep vein reflux.

Authors:  Dusan Pavcnik; John Kaufman; Lindsay Machan; Barry Uchida; Frederick S Keller; Josef Rösch
Journal:  Semin Intervent Radiol       Date:  2005-09       Impact factor: 1.513

6.  Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo.

Authors:  S Kaushal; G E Amiel; K J Guleserian; O M Shapira; T Perry; F W Sutherland; E Rabkin; A M Moran; F J Schoen; A Atala; S Soker; J Bischoff; J E Mayer
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

7.  Neovalve construction in postthrombotic syndrome.

Authors:  Oscar Maleti; Marzia Lugli
Journal:  J Vasc Surg       Date:  2006-04       Impact factor: 4.268

8.  Endothelial progenitor cells as a sole source for ex vivo seeding of tissue-engineered heart valves.

Authors:  Virna L Sales; Bret A Mettler; George C Engelmayr; Elena Aikawa; Joyce Bischoff; David P Martin; Alexis Exarhopoulos; Marsha A Moses; Frederick J Schoen; Michael S Sacks; John E Mayer
Journal:  Tissue Eng Part A       Date:  2010-01       Impact factor: 3.845

9.  Potential of baboon endothelial progenitor cells for tissue engineered vascular grafts.

Authors:  Monica T Hinds; MinHui Ma; Noi Tran; Ann E Ensley; Stephanie M Kladakis; Keri B Vartanian; Brandon D Markway; Robert M Nerem; Stephen R Hanson
Journal:  J Biomed Mater Res A       Date:  2008-09       Impact factor: 4.396

Review 10.  Endothelial progenitor cells: identity defined?

Authors:  Frank Timmermans; Jean Plum; Mervin C Yöder; David A Ingram; Bart Vandekerckhove; Jamie Case
Journal:  J Cell Mol Med       Date:  2009-01       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.